Gland Pharma Ltd

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1676.6, down 1.75% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.68% on the day, quoting at 24597.8. The Sensex is at 79386.06, down 0.79%.Gland Pharma Ltd has eased around 11.05% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 3.44% in last one month and is currently quoting at 23005.5, up 0.23% on the day. The volume in the stock stood at 50035 shares today, compared to the daily average of 84591 shares in last one month.The PE of the stock is 23.67 based on TTM earnings ending December 25.Powered by Capital Market - Live

The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc. Brimonidine Tartrate Ophthalmic Solution, 0.025% is indicated for the relief of redness of the eye. According to IQVIA data, the product recorded US sales of approximately $39 million for the twelve months ended September 2025. Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. The company reported a 27.7% increase in consolidated net profit to Rs 261.48 crore on a 22.5% rise in net sales to Rs 1,695.36 crore in Q3 FY26 as compared with Q3 FY25. The counter slipped 3.26% to Rs 1,736.60 on the BSE. Powered by Capital Market - Live

Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC). The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc. This Product is indicated to relieve redness of the eye. Powered by Capital Market - Live

Gland Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1856, up 1.07% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 25713.95. The Sensex is at 83408.99, down 0.05%. Gland Pharma Ltd has risen around 10.42% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has risen around 1.73% in last one month and is currently quoting at 22494.9, up 0.1% on the day. The volume in the stock stood at 53785 shares today, compared to the daily average of 2.63 lakh shares in last one month.The PE of the stock is 25.46 based on TTM earnings ending December 25.Powered by Capital Market - Live

Gland Pharma announced that Dr. Jitendra Gangwal has been appointed as Vice-President (Research and Development), a Senior Management Personnel of the Company with effect from 18 February 2026.Powered by Capital Market - Live

Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1857, up 1.13% on the day as on 10:24 IST on the NSE. The benchmark NIFTY is down around 0.21% on the day, quoting at 25670.3. The Sensex is at 83238.9, down 0.25%. Gland Pharma Ltd has gained around 10.48% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 1.57% in last one month and is currently quoting at 22494.9, down 0.05% on the day. The volume in the stock stood at 20707 shares today, compared to the daily average of 2.63 lakh shares in last one month.The PE of the stock is 25.46 based on TTM earnings ending December 25.Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) of InfoRLife. This Product is indicated to treat Hypercalcemia of Malignancy and Multiple Myeloma and Bone Metastases of Solid Tumors. According to IQVIA, the product had US sales of approximately USD 6.7 million for the twelve months ending November 2025. Powered by Capital Market - Live

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL), manufactured by InfoRLife. Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy, multiple myeloma, and bone metastases of solid tumors. According to IQVIA data, the product recorded US sales of approximately $6.7 million during the twelve months ended November 2025. Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. The counter shed 0.48% to Rs 1,840.95 on the BSE. Powered by Capital Market - Live

Gland Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1852, up 2.88% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 25293. The Sensex is at 82170.1, down 0.48%. Gland Pharma Ltd has added around 7.55% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 4.67% in last one month and is currently quoting at 21564, up 0.46% on the day. The volume in the stock stood at 3.46 lakh shares today, compared to the daily average of 2.85 lakh shares in last one month.The PE of the stock is 24.98 based on TTM earnings ending December 25.Powered by Capital Market - Live

Five-Star Business Finance Ltd, ABB India Ltd, Gillette India Ltd, Star Health & Allied Insurance Company Ltd are among the other stocks to see a surge in volumes on NSE today, 29 January 2026.Gland Pharma Ltd registered volume of 27.34 lakh shares by 14:14 IST on NSE, a 28.57 fold spurt over two-week average daily volume of 95695 shares. The stock rose 7.13% to Rs.1,810.10. Volumes stood at 2.33 lakh shares in the last session.Five-Star Business Finance Ltd registered volume of 90.56 lakh shares by 14:14 IST on NSE, a 13.19 fold spurt over two-week average daily volume of 6.87 lakh shares. The stock slipped 11.38% to Rs.444.25. Volumes stood at 8.98 lakh shares in the last session.ABB India Ltd notched up volume of 21.89 lakh shares by 14:14 IST on NSE, a 8.56 fold spurt over two-week average daily volume of 2.56 lakh shares. The stock rose 9.37% to Rs.5,516.00. Volumes stood at 4.19 lakh shares in the last session.Gillette India Ltd saw volume of 1.54 lakh shares by 14:14 IST on NSE, a 7.39 fold spurt over two-week average daily volume of 20794 shares. The stock increased 4.51% to Rs.8,223.00. Volumes stood at 16644 shares in the last session.Star Health & Allied Insurance Company Ltd witnessed volume of 27.23 lakh shares by 14:14 IST on NSE, a 6.59 times surge over two-week average daily volume of 4.13 lakh shares. The stock increased 2.28% to Rs.450.60. Volumes stood at 7.53 lakh shares in the last session.Powered by Capital Market - Live